Sponsor pipeline

Fudan University clinical trial pipeline

Get alerts when Fudan University's trials change

560 active trials 313 recruiting 83 Phase 3 32 disease areas 57 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-02

What changed in the last 30 days showing 40 of 57 changes on 20 trials

2026-09-17
Trial status changed: Recruiting → Withdrawn
Trial withdrawn: funding issue
Start date pushed: 2021-09-16 → 2026-09-13
Primary completion confirmed: September 2026 (last estimated September 2029)
NCT07814365 PBI for Low-risk Breast Cancer
2026-09-16
Trial status changed: Recruiting → Withdrawn
Trial withdrawn: funding issues and poor accrual
Start date pushed: 2025-01-15 → 2026-09-01
Primary completion confirmed: September 2026 (last estimated July 2029)
NCT07805538 Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy
2026-09-29
Primary completion pushed: 2026-06 → 2029-06
Completion pushed: 2028-06 → 2032-06
NCT05901428 TCb vs EC-T in High Risk ER+/HER2- Breast Cancer · Phase 3
2026-09-29
Primary completion pushed: 2027-11 → 2029-08
Recruitment opened
Completion pushed: 2029-11 → 2031-11
NCT07152782 T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis · Phase 2
2026-09-26
Primary completion pushed: 2027-01-30 → 2027-12-31
Completion pushed: 2027-04-30 → 2028-06-30
NCT07419880 Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory… · Phase 2
2026-09-30
Enrollment reopened
NCT06637150 Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer · Phase 3
2026-09-29
Recruitment opened
NCT07432178 CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk… · Phase 3
2026-09-29
Recruitment opened
NCT06787339 Capecitabine in Low Risk Triple Negative Breast Cancer · Phase 2
2026-09-26
Enrollment closed, study ongoing
NCT06447623 Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast… · Phase 3
2026-09-26
Recruitment opened
NCT07150208 T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis · Phase 2
2026-09-22
Recruitment opened
Enrollment increased: 154 → 196 participants
NCT07132463 Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for… · Phase 3
2026-09-11
Recruitment opened
NCT07554846 Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant… · Phase 3
2026-09-19
Recruitment opened
NCT07497919 A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive… · Phase 2
2026-09-17
Enrollment closed, study ongoing
Primary completion 2026-07-21, at least 262 days after the final estimate of 2025-11-01
Completion pushed: 2027-06-01 → 2027-07-01
NCT05759572 Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer · Phase 2
2026-09-15
Trial status changed: Unknown → Completed
Study completion 2026-09-01, at least 397 days after the final estimate of 2025-07
NCT06501378 Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC… · Phase 2
2026-09-11
Completed without a posted recruiting period
Primary completion 2026-07-25, at least 207 days after the final estimate of 2025-12-30
NCT07079436 EIT Evaluation of Pulmonary Ventilation With Different Ropivacaine Concentrations in…
2026-09-09
Trial status changed: Unknown → Completed
Trial sites expanded: 1 → 21 locations
Final enrollment: 876 participants (planned 400)
Study completion confirmed: January 2025 (last estimated March 2025)
NCT06574295 HTA of NIVATS Based on RWE
2026-09-04
Trial completed
Primary completion confirmed: August 2022 (last estimated September 2023)
NCT03856372 Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk…
2026-09-11
Interventions modified
NCT07638852 Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in… · Phase 2
2026-09-04
Interventions modified
Trial arms changed: 8 → 10
NCT06649331 Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer · Phase 2

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-09-29 NCT07846267 Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic… Phase 2 Not Yet Recruiting
2026-09-25 NCT07841236 ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer Phase 2 Recruiting
2026-09-25 NCT07841613 Exploring the Impact of Diurnal Variation on Coagulation Function in Patients Undering… Enrolling by Invitation
2026-09-23 NCT07837362 SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer Phase 2 Not Yet Recruiting
2026-09-22 NCT07835139 Hypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After… Recruiting
2026-09-21 NCT07829848 Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic… Recruiting
2026-09-21 NCT07829874 Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients… Phase 2 Not Yet Recruiting
2026-09-21 NCT07832279 1-Week Versus 3-Week PBI Recruiting
2026-09-17 NCT07825753 Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer Phase 2 Not Yet Recruiting
2026-09-17 NCT07825766 The Role of Total Abdominal Autonomic Nerve Preservation During the Resection of… Active, Not Recruiting

Active trials by phase

Early Phase 1
4
Phase 1
4
Phase 1/2
19
Phase 2
249
Phase 2/3
7
Phase 3
76
Phase 4
14
Not charted: 187 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 560

NCT IDTitleConditionStatusUpdated
Phase 4
NCT07711171 Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild… Type 2 Diabetes Mellitus Recruiting 2026-07-17
NCT07445022 RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma Melanoma Advanced Recruiting 2026-03-03
NCT06230055 Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With… HER2-negative Breast Cancer Recruiting 2025-11-25
NCT06195228 A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of… Advanced Thyroid Cancer Patients Who Received Target Therapy Recruiting 2025-08-14
NCT06090994 Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With… Colorectal Cancer Recruiting 2025-05-07
NCT06561620 Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients 3-year Disease-free Survival Recruiting 2024-08-22
NCT04790305 Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative… Carcinoma Breast Recruiting 2024-06-27
NCT07644663 The Effects of Different Anesthetics on the Brain's Neural Networks Electroencephalogram (EEG) Not Yet Recruiting 2026-06-12
NCT07358520 Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to… Proteinuria Not Yet Recruiting 2026-01-22
NCT05871437 Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast… Breast Cancer Not Yet Recruiting 2025-09-08
NCT06665334 To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA… Colorectal Cancer Not Yet Recruiting 2024-10-31
NCT06578299 Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated… Breast Cancer Stage IV Not Yet Recruiting 2024-08-29
NCT06061692 Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized… Cerebral Small Vessel Diseases Not Yet Recruiting 2023-09-29
NCT05860907 Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without… Breast Cancer Stage IV Not Yet Recruiting 2023-09-26
Phase 3
NCT06637150 Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer Breast Cancer Recruiting 2026-09-29
NCT05901428 TCb vs EC-T in High Risk ER+/HER2- Breast Cancer Hormone Receptor Positive HER-2 Negative Breast Cancer Recruiting 2026-09-28
NCT07432178 CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk… Breast Cancer Recruiting 2026-09-28
NCT07132463 Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for… Rectal Cancer Recruiting 2026-09-21
NCT07554846 Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant… Resectable Stage II-IIIa NSCLC Recruiting 2026-09-10
NCT07762885 Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ… Ductal Carcinoma In Situ, DCIS Recruiting 2026-08-13
NCT07207824 DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC Bladder (Urothelial, Transitional Cell) Cancer Recruiting 2026-07-21
NCT07528716 Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy Breast Cancer Recruiting 2026-07-08
NCT07615751 Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in… Breast Cancer Recruiting 2026-05-29
NCT06402708 Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) Thymic Carcinoma Recruiting 2026-04-27
NCT06964568 CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC Esophageal Carcinoma Recruiting 2026-04-17
See all 560 active Fudan University trials with filters →

Disease areas by active trials, top 10 of 32

Breast Cancer (137) · Colorectal Cancer (84) · Lung Cancer (36) · Non-Small Cell Lung Cancer (NSCLC) (36) · Triple-Negative Breast Cancer (33) · Gastric Cancer (31) · Pancreatic Cancer (25) · Esophageal Cancer (22) · Head & Neck Cancer (19) · Liver Cancer (17)

Get alerts when Fudan University's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free